Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 176

The DOI matches its Crossref record.

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis

Open access
Dumond, Julie B, Yeh, Rosa F, Patterson, Kristine B, Corbett, Amanda H, Jung, Byung Hwa, Rezk, Naser L, Bridges, Arlene S, Stewart, Paul W, Cohen, Myron S, Kashuba, Angela DM · 2007 · AIDS

Abstract

OBJECTIVES: To describe first dose and steady state antiretroviral drug exposure in the female genital tract. DESIGN: Non-blinded, single center, open-label pharmacokinetic study in HIV-infected women. METHOD: Twenty-seven women initiating combination antiretroviral therapy underwent comprehensive blood plasma and cervicovaginal fluid sampling for drug concentrations during the first dose of antiretroviral therapy and at steady-state. Drug concentrations were measured by validated HPLC/UV or HPLC-MS/MS methods. Pharmacokinetic parameters were estimated for 11 drugs by non-compartmental analysis. Descriptive statistics and 95% confidence intervals were generated using Intercooled STATA Release 8.0 (Stata Corporation, College Station, Texas, USA). RESULTS: For all antiretroviral drugs, genital tract concentrations were detected rapidly after the first dose. Drugs were stratified according to the genital tract concentrations achieved relative to blood plasma. Median rank order of highest to lowest genital tract concentrations relative to blood plasma at steady state were: lamivudine (concentrations achieved were 411% greater than blood plasma), emtricitabine (395%), zidovudine (235%) tenofovir (75%), ritonavir (26%), didanosine (21%), atazanavir (18%), lopinavir (8%), abacavir (8%), stavudine (5%), and efavirenz (0.4%). CONCLUSIONS: This is the first study to comprehensively evaluate antiretroviral drug exposure in the female genital tract. These findings support the use of lamivudine, zidovudine, tenofovir and emtricitabine as excellent pre-exposure/post-exposure prophylaxis (PrEP/PEP) candidates. Atazanavir and lopinavir might be useful agents for these applications due to favorable therapeutic indices, despite lower genital tract concentrations. Agents such as stavudine, abacavir, and efavirenz that achieve genital tract exposures less than 10% of blood plasma are less attractive PrEP/PEP candidates.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/qad.0b013e328270385a

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 176

Metadata

Authors
Dumond, J. B., Yeh, R. F., Patterson, K. B., Corbett, A. H., Jung, B. H., Rezk, N. L., Bridges, A. S., Stewart, P. W., Cohen, M. S., & Kashuba, A. D.
Venue
AIDS
Published
2007-09
Volume
21
Issue
14
Pages
1899-1907
ISSN
0269-9370 (ISSN-L)
OpenAlex
W2050494263
Cited by
176
References
0
FWCI
9.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. https://app.cochat.ai/papers/10.1097/qad.0b013e328270385a
The paper
Dumond, J. B., Yeh, R. F., Patterson, K. B., Corbett, A. H., Jung, B. H., Rezk, N. L., Bridges, A. S., Stewart, P. W., Cohen, M. S., & Kashuba, A. D. (2007). Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS. https://doi.org/10.1097/qad.0b013e328270385a

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.